Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Iris Energy Limited (IREN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Iris Energy Limited — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Iris Energy Limited trades at $40.52 (market cap $14.70B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.7× Iris Energy Limited's market cap, and Iris Energy Limited is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | IREN | |
|---|---|---|
Market Cap | $39.89B | $14.70B |
Sector | Health | Energy |
52-Week High | $491.22 | $76.41 |
52-Week Low | $278.09 | $15.40 |
Enterprise Value | $38.15B | $16.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
IREN trades at $41.11, down 1.46% on the day, amid a bearish technical signal with key support at $40. The company is transitioning from Bitcoin mining to AI infrastructure, with revenue growing from $501M in 2025 to a projected $757M in 2026. Recent earnings have missed expectations, but analyst sentiment remains largely positive with a consensus price target of $79.11, representing significant upside potential from current levels.
The outlook hinges on successful execution of its AI cloud strategy, with a $3.1B contracted ARR target by end-2026 being a key catalyst. However, risks include intense competition, high capital expenditure evidenced by negative investing cash flow, and recent earnings misses. The stock offers high growth potential but carries substantial execution risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Iris Energy Limited
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →
